DailyIQ
|
DailyIQ
|
Last updatedUpdating…

LKFT·Lakefront Biotherapeutics NV

$33.56
-0.53 (-1.55%)
Pre-Market
High
$33.56
Open
$32.34
Market Cap
1.96B
52W High
$36.24
Low
$32.31
P. Close
$33.56
P/E
3.29
52W Low
$25.68
Fwd P/E
-28.18
DailyIQ Est.
$27.04
Inst. Own.
30.1%
Short Interest
2.34%
Days to Cover
4.8
Technical Score (1D)
36
BEARISH
News Sentiment
64
BULLISH
On Nov 2, Lakefront Biotherapeutics NV announced that Dr. Mehdi Shahidi would join its Board of Directors as a Non‑Executive Independent Director. Dr. Shahidi, a physician‑scientist with more than two decades of experience in biopharma, was named to replace former board member Dr. Paulo Fontoura, who departed for Sanofi. The company highlighted Dr. Shahidi’s track record in drug development, regulatory success, and organizational building as assets that will strengthen strategic guidance and capital deployment for Lakefront’s preclinical pipeline. This appointment was reported as a move to bolster the company’s leadership and support its ongoing research efforts.
LOW TARGET
$21 -33.9%
5 analysts
MEAN TARGET
$31 -5.5%
8 analysts
HIGH TARGET
$44 +36.8%
2 analysts
PRICE RANGE
$21.38 - $44.25
SB / B / H / S / SS
1/1/5/5/3
DAILYIQ EST.
$27.04 (-16.4%)
37/ 100
Bearish
Overall: Bearish
✕Analyst target below current price
View full financials →

EPS

EstBeatMiss
$-0.36$-0.19$-0.03$0.14$0.31Q3'25Q3'26
QtrEstActual+/−
Q3'26$0.23 - -
Q3'25$-0.28$-0.18+37.0%

Revenue

EstBeatMiss
$41M$52M$63M$74M$84MQ3'25Q3'26
QtrEstActual+/−
Q3'26$46M - -
Q3'25 - $79M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

LKFT Stock Snapshot

NEUTRAL36/100
$32.38−$1.18 (3.5%)
Market cap
1.96B
P/E ratio
3.3
Day range
$32.31 – $33.56
News sentiment
64/100 · Bullish
Analyst target
$30.57 (-5.6%)
Consensus
Hold · 15 analysts
52-week range+26.1% off low · -10.7% from high
$25.68$36.24
Price $32.38 DailyIQ Est. $27.04

LKFT ranks mid-pack on momentum, neither leading nor lagging its peers by much. At this size, a single catalyst moves the stock further than it would a larger peer.

Behaviour On Record

What LKFT's own history says about today's numbers

Realized volatility (21d)
25.6% 23rd pct
Below its peak
-87.4%
vs 200-day average
+14.1%
Up days (1y)
51%

Lakefront Biotherapeutics NV is currently running 25.6% annualised volatility over the last 21 sessions. Measured against LKFT's own 13 years of daily returns rather than a market-wide average, that is the 23rd percentile — unusually subdued by its own history, against a typical reading of 33.3%.

LKFT is trading -87.4% below its running peak. Across 13 full years on file, its median worst-drawdown-in-a-year was -37.7%, and the deepest was -64.5% in 2020. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began, and where past declines also continued.

Price sits +14.1% from its 200-day moving average. Against every other day in its history, that gap ranks at the 76th percentile — a somewhat wider gap than its own norm. Over the past year LKFT closed higher on 51% of sessions, and it is currently 3 sessions into a rising streak.

On November specifically: over 13 years of records, LKFT finished the month higher 8 of 13 times, with a median return of +2.8% and an average of +0.0%. Its strongest month historically has been December at +6.0% on average, its weakest February at -5.4%.

Overnight risk is measurable too: LKFT has opened more than 2% away from the prior close in 559 of 3,266 sessions (17.1% of the time), with the largest gaps running +16.0% and -25.4%.

All figures computed from 3,267 daily closes between 2013-11-06 and 2026-11-05, split-adjusted, recomputed daily. Percentiles are against LKFT's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of LKFT's sector?

Lakefront Biotherapeutics NV sits in the Health Care sector, currently ranked 1st of 12 GICS sectors by relative-strength rotation score (weakening). Within its narrower Biotechnology industry group, LKFT ranks 7th of 15 tracked industries, weakening.

Sector rank
#1 of 12
Sector state
Weakening
Sector rotation score
100
Industry rank
#7 of 15

Options Market

What is the options market pricing for LKFT?

CallsPuts

For Lakefront Biotherapeutics NV's nearest expiry (2026-11-20, 14 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.67), with at-the-money implied volatility around 12.5%. The options market is pricing roughly a ±2.4% move by that expiry — a range of about $30.88–$32.42.

Put/call ratio (2026-11-20)
0.67
ATM implied volatility
12.5%
Total open interest
5
Expected move by 2026-11-20
±2.4% ($30.88–$32.42)

Analyst Consensus Estimates

What do analysts expect LKFT to earn?

Analysts expect Lakefront Biotherapeutics NV to earn -$1.26 per share in the fiscal year ending Dec 2026 and -$1.90 in the fiscal year ending Dec 2028, from 2 estimates. These are analyst forecasts, not company guidance, and later years rest on fewer analysts.

Quarter endingEPS estimateEPS rangeEPS analystsRevenue estimateRevenue analysts
Sep 2026-$0.19-$0.65 to $0.272--
Dec 2026-$0.80-$1.98 to $0.243--
Fiscal year endingEPS estimateEPS rangeEPS analystsRevenue estimateRevenue analysts
Dec 2026-$1.26-$3.56 to $0.803--
Dec 2027-$1.80-$2.80 to -$0.573--
Dec 2028-$1.90-$2.21 to -$1.582--

Analyst Rating Changes

Are analysts turning bullish or bearish on LKFT?

RBC Capital most recently upgraded Lakefront Biotherapeutics NV to Outperform on Sep 23, 2026 with a price target of $45 (from $26). Over the last 90 days, coverage has run 1 upgrade against 0 downgrades, a net bullish lean.

Latest action
RBC Capital: Outperform
90-day upgrades
1
90-day downgrades
0
Net rating momentum
+1
DateFirmActionRatingPrice target
Sep 23, 2026RBC CapitalUpgradeSector Perform → Outperform$26 → $45
Aug 11, 2026Morgan StanleyMaintainedEqual-Weight$30 → $26
Aug 11, 2026RBC CapitalMaintainedSector Perform$28 → $26
Feb 25, 2026RBC CapitalMaintainedSector Perform$32 → $33

Corporate Stakes

Which companies own a stake in LKFT?

27.59%held by GILD

Gilead Sciences, Inc. reports a stake in Lakefront Biotherapeutics NV on SEC Form 13F: 16.7M shares, about 27.59% of the company, worth $500.2M at the end of Q2 2026. At today's price that stake is worth $541.0M, about 0.25% of GILD's own market value.

Holder
GILD
Shares held
16.7M
Stake
27.59%
Value
$500.2M
HolderLast quarterShares% of LKFTValue at filingValue nowChange
Gilead Sciences, Inc. GILDUnchanged16.7M27.59%$500.2M$541.0M+8.2%

Form 13F lists US-listed shares held at quarter-end and is filed up to 45 days later. Stakes in private companies are not on it. Value now and Change put those same shares, adjusted for any stock split, at today's price against their reported quarter-end value, so they do not reflect buying or selling since.

News & sentiment

What is the news saying about LKFT?

LKFT rose 10.3% over the month to Nov 6. News tone held between 42 and 97 from Oct 6 to Oct 15, then dropped to 62 on Oct 20.

Daily close and news tone, Oct 6 to Nov 6
$30$33Oct 6: tone 42Oct 7Oct 8Oct 9Oct 12Oct 13: tone 42Oct 14: tone 65Oct 15: tone 97Oct 16Oct 19Oct 20: tone 63Oct 21: tone 47Oct 22Oct 23Oct 26Oct 27Oct 28Oct 29Oct 30Nov 2: tone 67Nov 3Nov 4Nov 5Nov 6Oct 6News toneNov 6123
  1. Oct 20 +3.2%
  2. Nov 4 +6.0%
  3. Nov 6 -3.6%
Latest stories naming Lakefront Biotherapeutics NV

Technical analysis

How strong is LKFT's momentum right now?

On the daily chart LKFT ranks at the 36th percentile for momentum against 1,060 stocks and ETFs, a bearish reading.

Momentum rank by timeframe0 = weakest, 100 = strongest
See what drives the rankThe inputs behind each timeframe's momentum rank, plus RSI, stochastics, Bollinger Bands and moving averages. Free with an account.

Institutional ownership

Are big funds buying or selling LKFT?

4 of the 17 tracked managers added to LKFT in their latest 13F and 12 trimmed. Together they own 2.5% of the company, worth $44.9M. Ameriprise Financial and UBS Group AG alone hold 2.4%.

4adding12trimming1unchanged
Largest holders by stake, latest 13FBar = share of LKFT
  1. 1Ameriprise Financial Inc2.10%
    $38.1M positionTrimmed 10.7% last quarter
  2. 2UBS Group AG0.28%
    $5.0M positionTrimmed 4.1% last quarter
  3. 3American Century Companies Inc0.07%
    $1.2M positionAdded 5.2% last quarter
  4. 4HRT Financial LP0.03%
    $519 positionTrimmed 61.6% last quarter
  5. 5RhumbLine Advisers0.01%
    $218.8K positionTrimmed 1.1% last quarter
  6. 6BNP Paribas Financial Markets0.01%
    $206.7K positionTrimmed 38.9% last quarter
  7. 7Royal Bank of Canada<0.01%
    $26.0K positionAdded 29.0% last quarter
  8. 8Mirae Asset Global Investments Co., Ltd.<0.01%
    $22.6K positionAdded 13.2% last quarter
  9. 9Citigroup Inc<0.01%
    $11.7K positionNew position last quarter
  10. 10Barclays PLC<0.01%
    $3.6K positionTrimmed 33.1% last quarter
Full holdings history

Discover more

How has LKFT done against its peers?

Over the six months to Nov 6, LKFT returned +12.3%. Of the 15 related stocks and ETFs, 12 did better, led by MRNA at +387.4%.

Change since May 6, through Nov 6
−200%0%+200%+400%+600%May 6JunJulAugSepOctNov 6MRNA +387.4%LKFT +12.3%INSM −22.2%